What you need to know about counterfeit medicines
Understand the risk of counterfeit medication.
Search
Our Commitment
Combating counterfeits requires a globally-coordinated effort of all public and private stakeholders affected. On a corporate basis and locally we actively support those initiatives by associations, law-enforcement authorities and governments. These are d
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Medicines reach record number of people, net sales rise
An Employee’s Commitment to Ensuring Access to Medicines
An Employee’s Commitment to Ensuring Access to Medicines
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned
Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
The findings demonstrate the benefit of clinic-level educational interventions
Ordering your medicine online? Find a safe pharmacy first.
Learn what to look for when buying medication and how to verify your pharmacy.
What can the Patient do?
What can the Patient do?
Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases
Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases
Clinical Trials
Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.
Propeller Health & BI Announce New Partnership | BI US
Propeller Health, the leading digital health solution for respiratory medicine and BI announce new partnership to help people living with COPD & asthma.
About our Innovation Prize
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
The Evolution of Biologic Medicines
Biologic Medicines & Biosimilars PDF
Confronting health disparities in clinical trials
As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.
Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
Our Innovation Prize | Partnering
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Fostering Science | Boehringer Ingelheim US
Find out how creating breakthrough medicines to change patients’ lives starts with a commitment to identify the challenges of the future & emerging science.
The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
A Planned Safety Net for Patients in Need
A Planned Safety Net for Patients in Need
Expanded Access Programs
Expanded Access Programs
FDA Grants OFEV® (nintedanib) BTD for Chronic Fibrosing ILDs | Boehringer Ingelheim US
FDA grants Breakthrough Therapy Designation to OFEV for chronic fibrosing ILDs with a progressive phenotype. View ISI, PI and Med Guide.